Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

This study has been completed.
Sponsor:
Collaborators:
Sanofi
Genentech
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00390416
First received: October 17, 2006
Last updated: January 17, 2012
Last verified: January 2012
  Purpose

This study is being done to find out what effects a drug named/called bevacizumab has on patients and patients' tumors when given together with standard chemotherapy drugs. Making new blood vessels seems to be important for many tumors to grow. Bevacizumab is a new type of treatment for cancer that blocks the growth of new tumor blood vessels. In this study, the researchers will combine bevacizumab with chemotherapy drugs that are standard for the patient's disease and include cisplatin, docetaxel, fluorouracil, and leucovorin. The way the original combination of cisplatin, docetaxel, and fluorouracil was given caused many side effects including gastrointestinal symptoms, weakness, and a drop in the blood count of infection fighting cells. For this study, the researchers have modified this combination to give lower doses of the medicines more often, to reduce side effects from the chemotherapy. Patients will receive bevacizumab with this modified combination of docetaxel, cisplatin, and fluorouracil. This study is called a phase II study. In this study, everyone will have similar tumors and receive the same treatment.


Condition Intervention Phase
Stomach Neoplasms
Esophageal Neoplasms
Drug: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • To determine the efficacy of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma as measured by 6 month progression free survival [ Time Frame: 6 month to progression free survival ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To establish the safety of modified docetaxel, cisplatin, and fluorouracil (mDCF) with bevacizumab in patients with unresectable or metastatic gastroesophageal adenocarcinoma [ Time Frame: prior to every cycle ] [ Designated as safety issue: Yes ]
  • To observe other measures of efficacy of mDCF with bevacizumab, including response rate, median progression free survival (PFS), overall and 1-year survival in patients with unresectable or metastatic gastroesophageal adenocarcinoma [ Time Frame: prior to every cycle ] [ Designated as safety issue: No ]
  • To explore coagulation activation in patients with unresectable or metastatic gastroesophageal adenocarcinoma [ Time Frame: pretreatment, cycle 1 week 1, cycle 2 week 1, cycle 3 week 1 ] [ Designated as safety issue: No ]
  • To explore the association of early FDG-PET/CT imaging with treatment efficacy [ Time Frame: baseline and week 3 (following the 2nd tx) ] [ Designated as safety issue: No ]
  • To bank tumor biopsy material for future planned correlative studies for association with chemotherapy efficacy and survival [ Time Frame: pretreatment ] [ Designated as safety issue: No ]

Enrollment: 46
Study Start Date: October 2006
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
    Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
Detailed Description:

Primary Objective

  • To determine the efficacy of modified docetaxel, cisplatin, and fluorouracil (mDCF) with bevacizumab in patients with unresectable or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma as measured by 6 month progression free survival (PFS)

Secondary Objectives

  • To establish the safety of mDCF with bevacizumab in patients with unresectable or metastatic gastroesophageal adenocarcinoma.
  • To observe other measures of efficacy of mDCF with bevacizumab, including response rate, median PFS, overall and 1-year survival in patients with unresectable or metastatic gastroesophageal adenocarcinoma.
  • To explore coagulation activation in patients with unresectable or metastatic gastroesophageal adenocarcinoma.
  • To explore the association of early FDG-PET/CT imaging with treatment efficacy.
  • To bank tumor biopsy material for future planned correlative studies for association with chemotherapy efficacy and survival.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed metastatic or unresectable gastric or esophageal adenocarcinoma, including GEJ adenocarcinoma which will be classified according to Siewert's classification type I, II, or III.
  • Histological documentation of local recurrence or metastasis is strongly encouraged, unless the risk of such a procedure outweighs the potential benefit of confirming the metastatic disease.
  • If no histologic confirmation, then the metastases or recurrence will require documentation by a 2nd radiographic procedure (i.e. positron emission tomography [PET] scan or magnetic resonance imaging [MRI] in addition to the computed tomography [CT] scan). If the imaging procedure does not confirm recurrent or metastatic disease, biopsy confirmation will be required.
  • Patients must have disease that can be evaluated radiographically. This may be measurable disease or non-measurable disease. Measurable disease is defined as that which can be measured in at least one dimension as > or = 20 mm with conventional techniques, or > or = 10 mm by high resolution imaging. Disease that is identified on radiology studies, but does not meet the criteria for measurable disease, is considered non-measurable - see section 12.1.1 of protocol for further details.
  • No prior chemotherapy for metastatic or unresectable disease. Patients may have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if more than 6 months have elapsed between the end of adjuvant therapy and registration. Patients may not have received prior docetaxel or cisplatin, or bevacizumab or any other novel biologic anti-angiogenic agent.
  • Age 18 years or older.
  • Karnofsky performance status > or = 70% (ECOG performance status 0-1).
  • Peripheral neuropathy < or = grade 1
  • Hematologic (minimal values):

    • White blood cell count > or = 3000/mm3
    • Absolute neutrophil count > or = 1500 cells/mm3
    • Hemoglobin > or = 9.0 g/dl
    • Platelet count > or = 100,000/mm3
  • Hepatic (minimal values):

    • Total bilirubin < or = to upper limit of normal (ULN)
    • AST and ALT and alkaline phosphatase must be within the eligible range. In determining eligibility, the more abnormal of the two values (AST or ALT) should be used. AST and ALT and alkaline phosphatase should be no more than 1-1.5 times the upper limit of normal.
  • Kidney function (minimal values):

    • Serum creatinine < or = 1.5 mg/dl
    • Urinalysis < 2+ proteinuria; urine protein (mg/dl)/urine creatinine (mg/dl) ratio (Up/c) < 1.0
  • The patient has a PT (INR) < or = 1.5 and a PTT < or = 3 seconds above the upper limits of normal if the patient is not on anticoagulation therapy. If a patient is on full-dose anticoagulants, the following criteria should be met for enrollment:

    1. The patient must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on stable dose of LMW heparin.
    2. The patient must not have active bleeding or pathological conditions that carry high risk of bleeding (e.g. tumor involving major vessels, known varices).
  • Women of childbearing potential must have a negative pregnancy test. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
  • Ability to understand informed consent and signing of written informed consent document prior to initiation of protocol therapy.

Exclusion Criteria:

  • Patients who have received previous chemotherapy for the treatment of metastatic or unresectable gastric, GEJ, or esophageal adenocarcinoma are ineligible. Patients who have received previous pre- or post-operative chemotherapy or chemoradiation are ineligible if therapy was completed less than 6 months prior to study registration. Patients must have recovered from adverse events from any previous therapy.
  • Patients who have received previous bevacizumab, docetaxel, or cisplatin.
  • Patients with a history of another neoplastic disease within the past three years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer.
  • Patients with brain or central nervous system metastases, including leptomeningeal disease.
  • Minor surgical procedure such as fine needle aspiration, core biopsy, laparoscopy, or mediport placement within 7 days prior to initiating treatment.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0
  • Anticipation of need for major surgical procedure during the course of the study.
  • Pregnant (positive pregnancy test) or breast feeding.
  • Urine protein:creatinine (Up/c) ratio > or = 1.0 at screening
  • History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to the initiation of treatment.
  • Serious, non-healing wound, ulcer, or bone fracture.
  • Blood pressure > 150/100 mmHg
  • Significant cardiac disease defined as:

    • Unstable angina
    • New York Heart Association (NYHA) grade II or greater
    • Congestive heart failure
    • History of myocardial infarction within 6 months
  • Evidence of bleeding diathesis or coagulopathy.
  • History of a stroke or cerebrovascular accident (CVA) within 6 months.
  • Clinically significant peripheral vascular disease.
  • Clinically significant hearing loss or ringing in the ears.
  • Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80.
  • Inability to comply with study and/or follow-up procedures.
  • Patients with any other medical condition or reason, in the investigator's opinion, that makes the patient unstable to participate in a clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00390416

Locations
United States, New Jersey
Memoral Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
United States, New York
Memorial Sloan-Kettering Cancer Center @ Suffolk
Commack, New York, United States, 11725
Memorial Sloan-Kettering Cancer Center 1275 York Avenue
New York, New York, United States, 10021
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
Rockville Centre, New York, United States, 11570
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital
Sleepy Hollow, New York, United States
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Sanofi
Genentech
Investigators
Principal Investigator: David Ilson, MD,PhD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00390416     History of Changes
Obsolete Identifiers: NCT00403468
Other Study ID Numbers: 06-096
Study First Received: October 17, 2006
Last Updated: January 17, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:
Metastatic
Gastroesophageal
Docetaxel
Cisplatin
Fluorouracil
Bevacizumab
Metastatic Gastroesophageal Adenocarcinoma
06-096

Additional relevant MeSH terms:
Adenocarcinoma
Neoplasms
Esophageal Neoplasms
Stomach Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Stomach Diseases
Docetaxel
Bevacizumab
Cisplatin
Fluorouracil
Leucovorin
Levoleucovorin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors

ClinicalTrials.gov processed this record on July 31, 2014